Exon Skipping

Blog Post

Clinical Trial Alert: Phase 1b/2a Study of WVE-N531 in a Subset of People Living with DMD

By Sujatha Gurunathan | March 11, 2022
dystrophin
Blog Post

Simply Stated: What is Duchenne Muscular Dystrophy?

By Sujatha Gurunathan | February 16, 2022
Blog Post

Muscular Dystrophy Association Awards 18 Grants Totaling Over $1.6 Million for Neuromuscular Disease Research

By Sujatha Gurunathan | November 5, 2021
Blog Post

FDA Approves Sarepta Therapeutics’ Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45

By Sujatha Gurunathan | February 25, 2021
Blog Post

Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatments

By Sujatha Gurunathan | November 17, 2020
Blog Post

FDA Accepts Sarepta Therapeutics’ New Drug Application for DMD Treatment Casimersen

By Sujatha Gurunathan | August 26, 2020
Blog Post

FDA Approves NS Pharma’s Viltepso for Treatment of DMD Amenable to Exon 53 Skipping

By MDA Staff | August 12, 2020
Blog Post

NS Pharma Announces Positive Results from Phase 2 Study of Viltolarsen in DMD

By Sujatha Gurunathan | June 3, 2020
Blog Post

Pfizer Announces Positive Results from Phase 1b Study of PF-06939926 for Treatment of DMD

By Sujatha Gurunathan | June 1, 2020
Blog Post

NS Pharma Launches Expanded Access Program for Viltolarsen

By Jeanene Swanson | March 9, 2020